Starting from 2-(2-aminoethyl)pyridine, a series of Ndiazinyl-N'-[2-(2-pyridyl)ethyl]thioureas was prepared via the (2-pyridyl)ethylisothiocyanate and was screened as non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Derivatives bearing a 3-pyridazinyl or a 4-pyrimidinyl moiety turned out to be the most potent compounds. However, they exhibited less activity than nevirapine or trovirdine.
The replicative cycle of human immunodeficiency virus (HIV) has a number of steps that could be considered adequate targets for chemotherapeutic intervention (De Clercq, 1994a . Since the enzyme reverse transcriptase (RT) is essential for virus replication, it provides a suitable target for blocking the spread of HIV infection. Thus, RT inhibitors are very effective agents against HIV. They can be divided into two classes: nucleoside analogues (such as AZT, ddC, ddI) and non-nucleoside RT inhibitors (NNRTIs; De Clercq, 1994a . Owing to the toxic side-effects of compounds of the first group, more efforts are at present devoted to the development of NNRTIs.
A novel class of compounds investigated in this context is characterized by a thiourea moiety. Out of a series of (het)arylalkyl-substituted thioureas, trovirdine (LY300046.HC1) turned out to be a potent and selective inhibitor of HIV-I RT (IC so 0.015 [.tM; Bell et al., 1995) . In the course of our ongoing attempts to exploit the bio-isosteric potential of the pyridazine, pyrimidine and the pyrazine system, diazine congeners of trovirdine became an object of interest. Compounds of type 1 have been patented (PT Lind, JM Morin Jr, R Noreen & RJ Ternansky, 1993. Compounds and methods for inhibition of HIV and related viruses. Patent application WO 93 03, 022); there are, however, no reports on their synthesis, spectroscopic data or their biological activities. (Heinisch et al., 1997) . Elemental analyses were performed by Mag. J Theiner (Institute of Physical Chemistry, University of Vienna, Austria). All analyses were within ±0.3% of the calculated values. Reactions were monitored byTLC using Polygram SIL GlUV 254 (Macherey-Nagel, Dueren, Germany) plastic-backed plates (0.25 mm layer thickness) and visualized using a UV lamp. Light petroleum refers to the fraction of b.p. 40-60°C.
2-(2-Pyridyl)ethylisothiocyanate (2)
A solution of thiophosgene (5.10 g, 44.2 mmol) in 80 mL of dich1oromethane was added to a stirred suspension of sodium hydrogen carbonate (8.94 g, 106 mmol) in 30 mL of water kept at O°C. To the vigorously stirred reaction mixture a solution of 2-(2-aminoethyl)pyridine (3; 5.00 g, 40.9 mmol) in 40 mL of dichloromethane was added drop-wise within 30 min. The mixture was then allowed to warm up to room temperature. Mter stirring for 4 h the aqueous layer was separated and extracted with dichloromethane (3x100 mL). The combined organic layer was washed with water (2x100 mL), saturated sodium chloride solution (lx100 mL), dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The oily residue was then purified by bulb to bulb distillation.
Colourless oil (88%); IH NMR I) (p.p.rn.) 8.57 (dd, J 36=1.1 Hz, J 56=5.4 Hz, 1H, pyridine H-6), 7.67 (dt, J 34=45=7.7 Hz, J 46=1.8 Hz, 1H, pyridine H-4), 7.27-7.17 (rn, 2H, pyridine H-3/5), 3.96 (t, J=6.7 Hz, 2H, CH), 3.16 (t, J=6.7 Hz, 2H, CH 2 ) ; l3C NMR I) (p.p.rn.) 156.7 (s, pyridine C-2), 149.5 (d, pyridine C-6), 136.8 (d, pyridine C-4), 123.8 (d, pyridine C-3), 122.1 (d, pyridine C-5),44.4 (t, CH 2), 38.2 (t, CHJ 444 General procedure for the synthesis of N-
A solution of freshly distilled (bulb to bulb) (2pyridyl)ethylisothiocyanate (2; 475 mg, 2.89 mmol) in 2 mL of anhydrous dioxane was added via a syringe to a stirred suspension ofsodium hydride (105 mg, 2.62 mmol, 60% dispersion in mineral oil) and the appropriate aminodiazine (3-aminopyridazine, 4-aminopyridazine, 2-aminopyrimidine, 4-aminopyrimidine or 2-aminopyrazine) (250 mg, 2.62 mmol) in 8 mL of anhydrous dioxane. Mter stirring for 16-24 h, the mixture was poured into water (100 mL) and was extracted with ethyl acetate (3x50 mL). The organic layer was washed with water (2x50 mL), saturated sodium chloride solution (lx50 mL), dried over anhydrous sodium sulphate, filtered and evaporated in vacuo. The solid residue was then recrystallized from ethyl acetate/light petroleum. (d,J s6=2.9 Hz, 1H, pyrazine H-5), 8.11 (dd,J 36=1.6 Hz,J S6=2.9 Hz, 1H, pyrazine H-6), 7. 77-7.68 (rn, 1H, pyridine H-4), 7.34-7.20 (rn, 2H, pyridine H-3/5) , 4.00 (rn, 2H, NH-CH 2 ) , 3.09 (t,J=6.7 Hz, 2H, CH 2 ) ; £1 MS m/e 259 (M+). Anal. calcd for C 12H13NsSxO.05light petroleum (262.94).
HIV-1 RT inhibition
The measurement of in vitro HIV-1 RT inhibition was performed with a non-radioactive Reverse Transcriptase Assay from Boehringer Mannheim. For exact composition and concentration of the solutions and for precise working procedure see instructions of the assay.
The compounds were dissolved in DMSO (20 mM) and further diluted with lysis buffer (solution 1, 5~lL of DMSO solution and 95 ul. oflysis buffer; solution 2, 10 ul. of solution 1 and 90 ul, oflysis buffer; solution 3, 10 ul, of solution 2 and 90 u.L oflysis buffer) shortly before use.
Test compounds. 5~lL ofRT dilution (5 ngwell-i), 15 ul, of lysis buffer, 20~lL of a solution of the compound (1-0.01 Antiviral Chemistry & Chemotherapy8 (5) Diazinyl-substituted thioureas against HIV-l RT mM in DMSO/lysis buffer) and 20~lL of reaction mixture (template and nucleotides) were incubated for 1 h at 37"C.
RT standards. 5~L of RT dilution (1, 2 or 5 ng well."), 35 u.L of lysis buffer and 20 u.L of reaction mixture (template and nucleotides) were incubated for 1 hat 37"C.
Blank value. 40~L of lysis buffer and 20~lL of reaction mixture (template and nucleotides) were incubated for 1 h at 37"C.
The reaction solutions were then transferred into streptavidin-coated microplate modules and incubated for 1 h at 37"C. The samples were discarded and plates were washed five times with washing buffer. After washing, 200~L of anti-DIG peroxidase conjugate (200 mU mL-i) was added to each well and the resulting mixtures were incubated for 1 h at 37"C. After additional washing (see above), 200~lL of POD substrate (2,2'-azinobis-3-ethylbenzothiazoline-6-sulphonate) were added to each well and the mixture was subsequently incubated at room temperature (10-15 min). The absorbance of the samples was measured at 405 nm with a reference wavelength at 490 nm using a micro titre plate (ELISA) reader. A procedure providing convenient access to N-tertbutyl-N'-diazinyl thioureas has been reported recently (Heinisch et al., 1995) . It consists of reaction of an appropriate aminodiazine with an isothiocyanate in the presence of sodium hydride in dimethylformamide solution. For the preparation of compounds of type I it turned out that l,4-dioxane has to be used as the solvent in order to make extraction of our significantly more polar target compounds possible. Under these conditions the thiourea derivatives la-e are formed smoothly, as indicated byTLC monitoring; the low yields of analytically pure materials obtained are due to loss on recrystallization. The required isothiocyanate 2 can be prepared in a two-step procedure consisting of sodium chlorite oxidation of the product obtained by addition of carbon disulphide to 3 (Rahman, 1980) or more conveniently in a one-pot reaction, i.e. treatment of (commercially available) 2-(2-aminoethyl)pyridine with thiophosgene in a two-phase system consisting of aqueous sodium bicarbonate solution and dichloromethane.
The thiourea derivatives of type la-e together with nevirapine (Hargrave et al., 1991) , the first NNRTI licensed (in the US) for clinical use in the treatment of AIDS (1996, Boehringer Ingelheim), as a reference were screened In vitro for inhibition of HIV-1 RT. Concentrations of330~LM, 33~LM and 3.3~LM were used. The results thus obtained are summarized in Table 1. Compounds la, c, d and e were found to inhibit RT. Out of this series the thiourea derivatives bearing a 3-pyridazinyl (La) or a 4-pyrimidinyl (ld) moiety turned out to be the most potent compounds but exhibited less activity than nevirapine or trovirdine. It seems that a nitrogen atom in the ortho position to the thiourea substructure is essential since the 4-pyridazinyl derivative (lb) is devoid of RT inhibitory activity.
